Prescription Drug Affordability Review Board
Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
- PDAB Members
- Dr. Sami Diab, MD of Greenwood Village, Colorado
- Dr. Amy Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger, RN, MHA of Holyoke, Colorado
- Board Chair, Dr. Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado
- Dr. James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
- PDAAC Members
- Kim Bimestefer, Executive Director of HCPF
- Gail DeVore, representing health care consumers
- Sarita Parikh, representing health care consumers
- Dr. Bob Mulch, representing statewide health care advocacy organizations
- PDAAC Chair, Dr. Kimberley Jackson, representing health care consumers living with chronic conditions
- Open position representing labor unions
- PDAAC Vice Chair, Nathan Wilkes, representing employers
- Open position representing carriers
- Marc Reese, representing PBMs
- Dr. Richard Miranda, representing health care professionals with prescribing authority
- Dr. Brett McQueen, representing research organizations
- Katelin Lucariello, representing brand name manufacturers
- Fayez Azeez, representing generic manufacturers
- Dr. Ingrid Pan, representing pharmacists
- Leah Lindahl, representing wholesalers
- Conflicts of Interest
PDAB Conflict of Interest Policy and Procedure
PDAB Conflict of Interest Disclosure
Announcements
- To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
- The Board will hold its second rulemaking hearing for Enbrel's upper payment limit on July 11, 2025. Link to register for the meeting can be found below.
- The data submission guide (DSG) is now available for public use. The DSG provides guidance for stakeholders that are interested in submitting information for the Board's consideration during the rulemaking hearing for Enbrel's upper payment limit (UPL). The DSG also includes details on how to submit confidential information.
- PDAAC is currently recruiting new council members to represent labor unions, carriers, and health care consumers. If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.
PDAB Meetings
The next PDAB meeting will be held on Friday, July 11, 2025 from 10 am - 1 pm MT.
Register for July 11 PDAB Meeting
- PDAB Meeting Materials Note: earlier meeting materials can be accessed by emailing dora_ins_pdab@state.co.us.
- DRAFT Cosentyx Addendum
- DRAFT Stelara Addendum
- 2025 PDAB/PDAAC Meeting Links & Recordings
PDAAC Meetings
The next PDAAC meeting will be held on Thursday, August 28 2025 from 9 - 11 am MT.
Register for August 28 PDAAC Meeting
- PDAAC Meeting Materials Note: earlier meeting materials can be accessed by emailing dora_ins_pdab@state.co.us.
- Adopted Policies
Office Hours
Office hours are an informal space for stakeholders to ask questions about PDAB processes and to provide resources for stakeholders to testify during rulemaking hearings. Office hours are currently on hold. For any questions or to provide resources, please email dora_ins_pdab@state.co.us.
PDAB Rulemaking
The UPL rulemaking for Enbrel began during the May 23 PDAB meeting. The second Enbrel UPL rulemaking hearing will be on July 11. The Board anticipates holding at least 3 rulemaking hearings for each drug. For more information on PDAB rulemaking and how to provide testimony during a PDAB rulemaking hearing, please visit the linked PDAB Rulemaking Guide.
Providing Public Comment
The PDAB welcomes general public comments during PDAB meetings. Comments are limited to 2 minutes per person. Public comment is not a time for the Board to interact with the public.
- Verbal Public Comment: To provide verbal comments, please fill out the sign up form that will be provided at each meeting. Public comments will be limited to 2 minutes per person.
- Written Public Comment: To provide written comments about general PDAB business or agenda items, please email dora_ins_pdab@state.co.us. Written comments will be accepted up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.
Providing Testimony
Verbal or written testimony occurs only during PDAB rulemaking hearings and will be included in the rulemaking record. The Board may ask questions of stakeholders during their testimony. Visit the PDAB Rulemaking Guide for more information on testifying at a PDAB rulemaking hearing.
- Verbal Testimony: To provide verbal testimony, please fill out the testimony sign up form. Verbal testimony may be limited in duration.
- Written Testimony: please submit written testimony via dora_ins_pdab@state.co.us. Written testimonies will be accepted up to 48 hours before each rulemaking hearing. Comments submitted after the 48-hour deadline will be considered for the following rulemaking hearing.
- PDAB Rules and Policies
- Previous PDAB Meeting Materials
Note: meeting materials not displayed on this website can be accessed by emailing dora_ins_pdab@state.co.us
- Activities Summary Reports
- 2023/2024 Affordability Review Activities